Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in ImmunologyOpen Access

Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlessandro Nanni CostaOMOlga MulasAMAngela Maria Mereu

Discussion

Loading...

Member takes

Overview

This review examines immunologic mechanisms and emerging therapies for autoimmune hemolytic anemia, indicating shifts in treatment strategies.

Key Points

  • Pathogenetic mechanisms in autoimmune hemolytic anemia reveal underlying immune dysregulation and B-cell expansion.
  • Emerging therapies include monoclonal antibodies targeting complement activation, offering new treatment avenues.
  • Glucocorticoids remain the standard first-line therapy, with new agents being utilized for treatment-refractory cases.
  • The evolving landscape of AIHA treatment suggests a shift towards precision medicine, guided by disease biology.

Cite This Study

Costa et al. (2025) studied this question.

synapsesocial.com/papers/68c1a26154b1d3bfb60dd53bhttps://doi.org/10.3389/fimmu.2025.1624667
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies2026
  2. 2Management of autoimmune hemolytic anemia2025
  3. 3[Treatment strategies for autoimmune hemolytic anemia].2025
  4. 4Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management2024 · 59 citations
  5. 5Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region2024